Physician profile
Shivinder Narwal
NPI 1184619488
$8,489.61
in general payments reported to CMS, 2019-2025
29 companies · $1,429 in 2025
The $1,429 reported for 2025 was more than what 84% of Pediatric Gastroenterology providers received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $684 · 2020: $169 · 2021: $862 · 2022: $761 · 2023: $1,205 · 2024: $3,380 · 2025: $1,429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,857 · Consulting Fee: $1,156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,857.23 |
| Consulting Fee | $1,156.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,018.33 | 2022-2025 | |
| Abbvie INC. | $1,208.91 | 2019-2025 | |
| Vivus LLC | $735.95 | 2021-2025 | Pancreaze |
| Regeneron Healthcare Solutions, INC. | $637.43 | 2022-2025 | Dupixent |
| Neuraxis, INC. | $613.88 | 2024-2025 | |
| Qol Medical, LLC | $582.52 | 2019-2025 | Sucraid, Sucraid |
| Nestle Healthcare Nutrition INC. | $482.82 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $465.76 | 2024-2025 | Zenpep |
| Takeda Pharmaceuticals U.S.A., INC. | $329.50 | 2022-2025 | Gattex, Eohilia |
| Evoke Pharma, INC. | $279.71 | 2023-2025 | Gimoti |
| Astrazeneca Pharmaceuticals LP | $193.55 | 2021-2022 | |
| Regeneron Pharmaceuticals, INC. | $183.11 | 2022-2024 | Dupixent |
| Alcresta Therapeutics, INC. | $132.36 | 2024-2025 | Relizorb |
| Pharming Healthcare, INC. | $108.96 | 2023-2024 | Ruconest |
| Ironwood Pharmaceuticals, INC | $105.00 | 2023-2024 | Linzess |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $79.65 | 2019-2025 | Immunocap |
| Ipsen Biopharmaceuticals, INC | $58.20 | 2024 | Bylvay |
| Sandoz INC. | $35.22 | 2023 | Hyrimoz |
| Coloplast Corp | $34.19 | 2019 | |
| Mirum Pharmaceuticals, INC. | $32.84 | 2024 | Livmarli |
| Soleno Therapeutics, INC. | $31.29 | 2025 | Vykat Xr |
| Janssen Biotech, INC. | $27.48 | 2025 | Tremfya |
| Organon LLC | $23.18 | 2024 | |
| Travere Therapeutics, INC. | $21.44 | 2019 | |
| Allergan, INC. | $18.67 | 2019 | |
| Gilead Sciences, INC. | $17.68 | 2023 | |
| Aytu Biopharma, INC. | $15.58 | 2019 | |
| Capsovision, INC. | $15.40 | 2025 | Capsocam Plus |
| Romark Laboratories, Lc | $1.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivinder Narwal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.